{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06070649",
            "orgStudyIdInfo": {
                "id": "2000035937"
            },
            "secondaryIdInfos": [
                {
                    "id": "1R21AA030649-01A1",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/1R21AA030649-01A1"
                }
            ],
            "organization": {
                "fullName": "Yale University",
                "class": "OTHER"
            },
            "briefTitle": "The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)",
            "officialTitle": "The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)",
            "therapeuticArea": [
                "Other"
            ],
            "study": "the-potential-therapeutic-effects-of-psychedelic-n-n-dimethyltryptamine-dmt-on-alcohol-use-disorder-aud"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-08-15",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-09-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-09-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-08-16",
            "studyFirstSubmitQcDate": "2023-10-01",
            "studyFirstPostDateStruct": {
                "date": "2023-10-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Anahita Bassir Nia",
                "investigatorTitle": "Assistant Professor of Psychiatry",
                "investigatorAffiliation": "Yale University"
            },
            "leadSponsor": {
                "name": "Yale University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This proposed study is a double-blind, randomized, placebo-controlled, parallel-group, laboratory study to determine the effects of DMT, plus psychotherapy, on Alcohol Use Disorder.",
            "detailedDescription": "This study is a placebo-controlled, randomized, double blind, clinical trial to investigate the safety, tolerability and efficacy of the psychedelic dimethyltryptamine (DMT), in addition to a short course of psychotherapy, on Alcohol Use Disorder (AUD). The investigators hypothesize that relative to control (0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion plus psychotherapy), a single psychedelic dose of DMT (plus psychotherapy) in individuals with AUD will 1) be safe and 2) well-tolerated, and 3) reduce alcohol consumption measured in the laboratory the day after, and over the following 8 weeks."
        },
        "conditionsModule": {
            "conditions": [
                "Alcohol Use Disorder (AUD)",
                "Alcohol-Related Disorders",
                "Alcohol Use"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "OTHER",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 63,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Group 1",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Bolus of 0.3mg/kg/min DMT (5min) + Normal Saline infusion (60 min)",
                    "interventionNames": [
                        "Drug: 0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion"
                    ]
                },
                {
                    "label": "Group 2",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Bolus of 0.2 mg/kg/min DMT (5 min) + 0.01mg/kg/min infusion (60 min)",
                    "interventionNames": [
                        "Drug: 0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion"
                    ]
                },
                {
                    "label": "Group 3",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Bolus of 25 mg Diphenhydramine (5 min) + Normal Saline infusion (60 min)",
                    "interventionNames": [
                        "Drug: 25 mg Diphenhydramine (5 min) + Normal Saline"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion",
                    "description": "Infusion",
                    "armGroupLabels": [
                        "Group 1"
                    ],
                    "otherNames": [
                        "Moderate Dose DMT"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion",
                    "description": "Infusion",
                    "armGroupLabels": [
                        "Group 2"
                    ],
                    "otherNames": [
                        "Low Dose DMT"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "25 mg Diphenhydramine (5 min) + Normal Saline",
                    "description": "Infusion",
                    "armGroupLabels": [
                        "Group 3"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety and tolerability of DMT in women and men with AUD",
                    "description": "Systematic Assessment for Treatment Emergent Effects (SAFTEE) and MedDRA will be used weekly for 8 weeks to assess safety and tolerability of DMT in women and men with AUD.",
                    "timeFrame": "Day 0 through Day 56"
                },
                {
                    "measure": "The effects of DMT, plus psychotherapy, on alcohol consumption",
                    "description": "We will assess the desire of participants to drink alcohol in an experimental setting using the Alcohol Drinking Paradigm.",
                    "timeFrame": "Day 0 through Day 56"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "The relationship between acute psychedelic effects of DMT and alcohol consumption",
                    "description": "The Mystical Experience Questionnaire (MEQ) will be used to assess the relationship between acute psychedelic effects of DMT and alcohol consumption.",
                    "timeFrame": "Day 0 through Day 56"
                },
                {
                    "measure": "The relationship between acute psychedelic effects of DMT and alcohol consumption",
                    "description": "The Ego-Dissolution Inventory (EDI) will be used to assess the relationship between acute psychedelic effects of DMT and alcohol consumption.",
                    "timeFrame": "Day 0 through Day 56"
                },
                {
                    "measure": "The long-term effects of a single dose of DMT, plus psychotherapy, on alcohol consumption over the subsequent 8 weeks.",
                    "description": "The Timeline Followback (TLFB) approach will be used to assess the long-term effects of a single dose of DMT, plus psychotherapy on alcohol consumption.",
                    "timeFrame": "Day 0 through Day 56"
                },
                {
                    "measure": "The long-term effects of a single dose of DMT, plus psychotherapy, on alcohol consumption over the subsequent 8 weeks.",
                    "description": "Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES) will be used to assess the long-term effects of a single dose of DMT, plus psychotherapy on alcohol consumption.",
                    "timeFrame": "Day 0 through Day 56"
                },
                {
                    "measure": "The long-term effects of a single dose of DMT, plus psychotherapy, on alcohol consumption over the subsequent 8 weeks.",
                    "description": "Substance use disorder behaviors and risks with the Brief Addiction Monitor (BAM) will be used to assess the long-term effects of a single dose of DMT, plus psychotherapy on alcohol consumption.",
                    "timeFrame": "Day 0 through Day 56"
                },
                {
                    "measure": "The prosocial effects of DMT, plus psychotherapy, and changes in personality traits",
                    "description": "Prosocial effects with be assessed using the Prosocial Personality Battery (PSP). The scale consists of 56 total items and uses a Likert-type scale with 5 answer-choices.",
                    "timeFrame": "Day 0 through Day 56"
                },
                {
                    "measure": "The prosocial effects of DMT, plus psychotherapy, and changes in personality traits",
                    "description": "Prosocial effects with be assessed using the Social Connectedness Scale - Revised (SCS-R).",
                    "timeFrame": "Day 0 through Day 56"
                },
                {
                    "measure": "The prosocial effects of DMT, plus psychotherapy, and changes in personality traits",
                    "description": "Prosocial effects with be assessed using the Mindful Attention Awareness Scale (MAAS).",
                    "timeFrame": "Day 0 through Day 56"
                },
                {
                    "measure": "The relationship between the intensity of subjective psychedelic experience with lifetime history of chronic stress and trauma",
                    "description": "The Life Events Checklist (LEC) will be used to assess the relationship between the intensity of subjective psychedelic experience with lifetime history of chronic stress and trauma.",
                    "timeFrame": "Day 0 through Day 56"
                },
                {
                    "measure": "The relationship between the intensity of subjective psychedelic experience with lifetime history of chronic stress and trauma",
                    "description": "The Childhood Trauma Questionnaire (CTQ-SF) will be used to assess the relationship between the intensity of subjective psychedelic experience with lifetime history of chronic stress and trauma.",
                    "timeFrame": "Day 0 through Day 56"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnostic and Statistical Manual of Mental Disorders-5th edition (DSM-5) diagnosis of Alcohol Use Disorder\n* Medically healthy\n* Ability to provide consent\n\nExclusion Criteria:\n\n* Unstable medical conditions",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "21 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Angelina Contreras",
                    "role": "CONTACT",
                    "phone": "(203) 974-7525",
                    "email": "angelina.contreras@yale.edu"
                },
                {
                    "name": "Ardavan Mohammad Aghaei",
                    "role": "CONTACT",
                    "email": "ardavan.mohammadaghaei@yale.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Anahita Bassir Nia, MD",
                    "affiliation": "Yale University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Connecticut Mental Health Center",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06519",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Anahita Bassir Nia, MD",
                            "role": "CONTACT",
                            "email": "anahita.bassirnia@yale.edu"
                        },
                        {
                            "name": "Anahita Bassir Nia, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000437",
                    "term": "Alcoholism"
                },
                {
                    "id": "D000019973",
                    "term": "Alcohol-Related Disorders"
                },
                {
                    "id": "D000000428",
                    "term": "Alcohol Drinking"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004327",
                    "term": "Drinking Behavior"
                },
                {
                    "id": "D000019966",
                    "term": "Substance-Related Disorders"
                },
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3774",
                    "name": "Alcohol Drinking",
                    "asFound": "Alcohol Use",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21842",
                    "name": "Alcohol-Related Disorders",
                    "asFound": "Alcohol-Related Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3783",
                    "name": "Alcoholism",
                    "asFound": "Alcohol Use Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7502",
                    "name": "Drinking Behavior",
                    "relevance": "LOW"
                },
                {
                    "id": "M21837",
                    "name": "Substance-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000004155",
                    "term": "Diphenhydramine"
                },
                {
                    "id": "D000011398",
                    "term": "Promethazine"
                },
                {
                    "id": "D000004130",
                    "term": "N,N-Dimethyltryptamine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000068776",
                    "term": "Sleep Aids, Pharmaceutical"
                },
                {
                    "id": "D000006993",
                    "term": "Hypnotics and Sedatives"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000779",
                    "term": "Anesthetics, Local"
                },
                {
                    "id": "D000000777",
                    "term": "Anesthetics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000000932",
                    "term": "Antiemetics"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000005765",
                    "term": "Gastrointestinal Agents"
                },
                {
                    "id": "D000006634",
                    "term": "Histamine H1 Antagonists"
                },
                {
                    "id": "D000006633",
                    "term": "Histamine Antagonists"
                },
                {
                    "id": "D000018494",
                    "term": "Histamine Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000018926",
                    "term": "Anti-Allergic Agents"
                },
                {
                    "id": "D000000982",
                    "term": "Antipruritics"
                },
                {
                    "id": "D000003879",
                    "term": "Dermatologic Agents"
                },
                {
                    "id": "D000006213",
                    "term": "Hallucinogens"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                },
                {
                    "id": "D000012702",
                    "term": "Serotonin Antagonists"
                },
                {
                    "id": "D000018490",
                    "term": "Serotonin Agents"
                },
                {
                    "id": "D000017366",
                    "term": "Serotonin Receptor Agonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3777",
                    "name": "Ethanol",
                    "relevance": "LOW"
                },
                {
                    "id": "M7314",
                    "name": "N,N-Dimethyltryptamine",
                    "asFound": "Sinus Surgery",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14268",
                    "name": "Promethazine",
                    "asFound": "Reserve",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7338",
                    "name": "Diphenhydramine",
                    "asFound": "Reserve",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9305",
                    "name": "Hallucinogens",
                    "relevance": "LOW"
                },
                {
                    "id": "M10043",
                    "name": "Hypnotics and Sedatives",
                    "relevance": "LOW"
                },
                {
                    "id": "M4107",
                    "name": "Anesthetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M4109",
                    "name": "Anesthetics, Local",
                    "relevance": "LOW"
                },
                {
                    "id": "M4251",
                    "name": "Antiemetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M8881",
                    "name": "Gastrointestinal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M9708",
                    "name": "Histamine",
                    "relevance": "LOW"
                },
                {
                    "id": "M9710",
                    "name": "Histamine H1 Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M212144",
                    "name": "Histamine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M9709",
                    "name": "Histamine Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20962",
                    "name": "Anti-Allergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7074",
                    "name": "Dermatologic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                },
                {
                    "id": "M15512",
                    "name": "Serotonin",
                    "relevance": "LOW"
                },
                {
                    "id": "M19648",
                    "name": "Serotonin Receptor Agonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                },
                {
                    "abbrev": "AAll",
                    "name": "Anti-Allergic Agents"
                },
                {
                    "abbrev": "Derm",
                    "name": "Dermatologic Agents"
                },
                {
                    "abbrev": "AnEm",
                    "name": "Antiemetics"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                }
            ]
        }
    },
    "hasResults": false
}